Subject: Re: Chicken Soup and 141W94 (Vertex/Glaxo PI)
Date: Mon, Jan 26, 1998 15:10 EST
From: JWhite6892
Message-id: <19980126201001.PAA06973@ladder02.news.aol.com>
From Painne Webber (1/26/98): KEY DATA ON OTHER PROTEASE INHIBITORS AND SELECTIVE NEW REVERSE TRANSCRIPTASE INHIBITORS::
-141W94 (GLAXO/VERTEX PROTEASE INHIBITOR)- A Phase II clinical trial evaluated the efficacy of a four drug twice daily regimen of abacavir (1592), 141W94, and AZT/3TC in a small patient population. This four drug BID regimen appears potent, safe, and well tolerated, and provides sustained suppression of plasma viral load. 70% (14/20 patients), 67% (8/12 patients) and 63% (5/8 patients) response was noted at weeks 8, 12 and 20, respectively (Abstract
363). Although promising, given the small size of this study, the issue is demonstrating comparable or better efficacy in a larger patient poAnother combination study 141W94 and 1592 (Abstract 365) demonstrates in a small patient population (50 enrolled) sustained reduction in viral load up to week 16 in 7 antiretropviral naive patients. Four patients experienced rash and two discontinued therapy due to rash. Again, although promisisng, given the
small size of this study, the issue is demonstrating comparable efficacy and determining the side effect profile (e.g., incidence of rash) in a larger patient population".
My interpretation of this is that VRTX's PI is a lot worse than anyone thought, wait till after 5 Feb, but these results combined with the news of the BBB results compared to Indinavir, only strengthens Viracept position. Other data from available abstracts will only further Viracepts mkt position.!!!!
Shorts will cover...
|
